FULL PUBLISHED RESEARCHEarnings and management commentary analysis
Sage PRO · Quarter ended 30 September 2026 · 18 November 2026
Stance: Watch. Care Health’s premium growth and the restart of secured lending give Religare two routes to improve recurring earnings. The current wider consolidated loss makes normalized cash generation and disciplined capital deployment the tests of the thesis.
1. Investment decision
Key takeaways
- Care Health’s premium growth and the restart of secured lending give Religare two routes to improve recurring earnings.
- The current wider consolidated loss makes normalized cash generation and disciplined capital deployment the tests of the thesis.
- Religare is a registered core investment company.
Treat the listed entity as a holding company and assess operating subsidiaries on their own capital and profit bases. The 17 November reference market cap was about ₹7,550 crore.
2. Financial quality
Key takeaways
- Quarterly consolidated income rose 14.4% YoY to ₹2,389.75 crore, but expenses rose about 23.9% to ₹2,517.54 crore.
- PBT moved from a profit of ₹57.45 crore to a loss of ₹127.79 crore, a ₹185.24 crore deterioration.
- The group net loss was ₹97.69 crore, of which ₹49.98 crore was attributable to owners.
The remaining ₹47.71 crore loss belonged to non-controlling interests. Use attributable earnings when evaluating the listed equity. Consolidated total comprehensive loss was ₹225.54 crore after negative OCI, making the effects of earnings, valuation changes and capital movements distinct parts of the equity bridge.
3. Care Health and broking
Key takeaways
- Care Health’s H1 gross written premium reached ₹6,897 crore, up 35% on the issuer’s reported premium basis.
- H1 PBT rose 42% to ₹392 crore under Ind AS.
- The insurance service ratio improved 70 basis points to 100.5%.
A ratio around 100% makes pricing discipline, claims trends and investment income important to overall profitability. Premium growth alone gives limited information about distributable cash. Broking generated ₹97.4 crore in Q2 income and ₹13 crore H1 PBT. The ₹100 crore rights subscription supports activities including margin financing. Track the associated spread, collateral quality and cost of equity alongside trading volumes.
4. Finvest restart and mortgage credit
Key takeaways
- On the earnings call, management attributed Finvest’s Q2 NII increase to recoveries in the legacy nonperforming pool.
- The deck gives ₹39.3 crore versus ₹18.5 crore a year earlier, and Finvest PAT was ₹49.4 crore versus ₹30.8 crore.
- Its first newly originated loan was disbursed in November, after the quarter closed.
Report Q2 recoveries separately from post-quarter origination. Finvest’s reported zero net NPA and surplus capital describe the residual book and initial funding headroom. New loan cohorts will need separate underwriting and loss histories. The housing subsidiary reported ₹243 crore AUM and gross NPA of 3.5%, down from 4.4% in June. Assess whether the improvement comes from cash collections, cures or portfolio changes before projecting credit costs.
5. Funding and capital allocation
Key takeaways
- Finvest reported roughly ₹963 crore net worth and ₹660 crore of cash and liquid investments with no borrowings.
- Model the liquidity available to the subsidiary separately from money available to the listed parent.
- Group filings describe contingent recovery-sharing obligations linked to former lenders and disputed deposits.
Assess recoverable assets and associated obligations together. The parent subscribed about ₹119.69 crore to Care Health in June and ₹100 crore to Religare Broking in September. The September quarter also saw 35 lakh warrant conversions and ₹61.68 crore of cash proceeds. When estimating equity value per share, include fresh cash and the related ordinary shares consistently.
6. Valuation and restructuring
Key takeaways
- A sum-of-the-parts analysis is more informative than capitalizing consolidated Q2 earnings.
- Value Care Health with insurer-specific underwriting, investment income and solvency assumptions.
- Value Finvest and the housing subsidiary on sustainable ROE and required capital after separating recoveries from new loan margins.
Use through-cycle earnings and capital requirements for broking. Apply verified ownership, then adjust for parent liabilities, contingent obligations and recurring corporate overhead. At the 17 November snapshot, the market cap was about ₹7,550 crore. An exact fair-value target requires independently matched subsidiary valuations and a fully diluted share bridge. The filing says the RBI did not accede to the current demerger application in August. The scheme stays outside the base case pending a fresh documented approval.
7. Scenarios and monitoring
Bear: Care Health’s underwriting deteriorates, Finvest recoveries fade before new lending covers its costs, and parent capital commitments remain elevated. Base: Care Health grows with a stable or gradually improving insurance service ratio, while Finvest remains an early-stage secured lending rollout. Bull: Better underwriting and measured branch expansion improve recurring attributable earnings and capital returns. The first checks are Care Health’s claims and expense bridge, Finvest’s new-book disbursements and collections by vintage, and cash remaining at the listed parent after investments and debt commitments. A widening consolidated loss alongside persistently rising subsidiary funding needs would weaken the thesis.
Evidence and limitations
Key takeaways
- Investor presentation, statutory results and 13 November written earnings-call transcript reviewed.
- The written rendering is supplemental to the exchange-filed call recording.
- Operating scenarios are analytical cases.
Loan-cohort, claims and diluted valuation detail remain diligence items.
-
Additional earnings and capital analysis
Key takeaways
- The reported ₹300.84 crore year-on-year increase in consolidated quarterly income was outweighed by approximately ₹486.07 crore of incremental expenses.
- This explains the direction and scale of the PBT deterioration.
- It also shows why the insurer’s stronger H1 operating figures cannot be used on their own to infer a group turnaround.
Reconcile insurer underwriting, investment income, intercompany eliminations, corporate expenses and minorities before translating segment performance into parent cash generation. Finvest Q2 PAT increased by ₹18.6 crore YoY, but the call linked much of the operating improvement to the legacy book. A practical test is to track new originations separately from recovery collections and measure loan yields after cost of funds, acquisition and servicing expense.
A separate underwriting sensitivity for Care Health should hold premiums and investment earnings constant while varying insurance service expenses. Applying the ratio directly to gross written premium risks mixing reporting bases. For the listed parent, watch whether recurring subsidiary dividends cover recurring interest and central costs before assigning value to prospective restructuring.